Current best evidence for clinical care (more info)
Evidence on COVID-19 vaccine efficacy/effectiveness (VE) in preventing asymptomatic SARS-CoV-2 infections is needed to guide public health recommendations for vaccinated people. We report interim results of a living systematic review. We identified a total of 30 studies that investigated VE against symptomatic and/or asymptomatic infection. In fully vaccinated individuals, VE against symptomatic and asymptomatic infections was 80-90% in nearly all studies. Fully vaccinated persons are less likely to become infected and contribute to transmission.
| Discipline / Specialty Area | Score |
|---|---|
| Family Medicine (FM)/General Practice (GP) | |
| General Internal Medicine-Primary Care(US) | |
| Public Health | |
| Pediatrics (General) | |
| Internal Medicine | |
| Infectious Disease | |
This is relevant to my work. Limitations of the review are clearly stated. I found this a good read and informative.
This is a very important article that will help tremendously medical practice.
This is a moving target, obviously. It would be great if we could assemble knowledge about vaccine efficacy (VE), but it is a huge challenge. We do not know the duration of protection (which seems to be months but not years) or what new variations will come along. The ongoing nature of this systematic review is helpful; although, not everything will be published in the most timely manner.
This paper is a meta-analysis of studies of coronavirus vaccine efficacy. Once again, efficacy for both symptomatic and asymptomatic infections was high. This paper has limited relevance in the United States as all papers reviewed preceded the delta variant outbreak that is causing the vast preponderance of disease.
This is a timely review reporting on the effectiveness/efficacy of COVID-19 vaccines, all showing evidence of protection from infection. I am concerned though that the included studies were mostly observational with high risk of bias. Only 2 RCTs were included, with one of them being of good quality. We need more RCTs of high quality to examine vaccine effectiveness, as well as safety.